Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Markus P. Schlaich(The University of Western Australia), Murray Esler(Baker Heart and Diabetes Institute), Élisabeth Lambert(Swinburne University of Technology), Paul A. Sobotka(The Ohio State University), Henry Krum(Australian Regenerative Medicine Institute)
Cited by 774
Related Papers
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
|European Journal of Heart Failure|2012|1.1k